Barrington Research Maintains Outperform on Haemonetics, Raises Price Target to $145
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
Barrington Research analyst Michael Petusky maintains Haemonetics (NYSE:HAE) with a Outperform and raises the price target from $140 to $145.
Barrington Research analyst Michael Petusky maintains Haemonetics (NYSE:HAE) with a Outperform and raises the price target from $140 to $145.